Cardiology Conference: “Practice-Changing” Data On Device Interventions
This article was originally published in The Gray Sheet
Executive Summary
Late-breaking clinical trials of coronary stent and related interventions are bringing both practice-changing and surprising results, according to physicians who attended a major cardiology meeting in Chicago last week
You may also be interested in...
New Products In Brief
Bausch & Lomb gets approval for first-of-a-kind intraocular lens. Roche HbA1c assay is first to be cleared to diagnose diabetes. More product launches and approvals from the past week.
Research In Brief
Drug-coated angioplasty balloon: Percutaneous treatment of femoropopliteal disease with paclitaxel-coated angioplasty balloons was associated with reduced six-month lumen loss and target-lesion revascularization rates compared to regular angioplasty balloons in the 154-patient randomized THUNDER trial sponsored by Bavaria Medizintechnologie and Schering. Results appear in the Feb. 14 issue of the New England Journal of Medicine. THUNDER is a small preliminary study and larger trials are needed to confirm the benefits of drug-coated balloons, according to authors Gunnar Tepe, M.D., University of Tübingen, et al
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”